GlassScriptPhysician profile
Craig Fredrick Mccabe
NPI 1396747325
$80,955.66
in general payments reported to CMS, 2019-2025
38 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $1,097 · 2021: $1,738 · 2022: $4,214 · 2023: $25K · 2024: $9,920 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $8,057 · Food and Beverage: $6,905 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,450.00 |
| Travel and Lodging | $8,056.78 |
| Food and Beverage | $6,904.62 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $49,654.92 | 2022-2025 | |
| Allergan, INC. | $14,241.71 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $5,436.61 | 2019-2021 | |
| Alcon Vision LLC | $3,661.79 | 2019-2025 | Clareon, Hydrus Microstent, Ngenuity |
| Johnson & Johnson Surgical Vision, INC. | $3,091.96 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Eyevance Pharmaceuticals LLC | $1,309.35 | 2019 | |
| Genentech USA, INC. | $366.08 | 2023-2025 | Vabysmo |
| Nova Eye, INC. | $314.74 | 2023-2024 | |
| New World Medical,INC. | $249.93 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $247.27 | 2019-2021 | |
| Sight Sciences, INC. | $243.20 | 2020-2025 | Omni Surgical System |
| Ocular Therapeutix, INC. | $223.85 | 2022-2025 | Dextenza |
| Dompe US, INC. | $203.18 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $184.67 | 2019-2021 | |
| Rxsight INC | $182.95 | 2021-2023 | Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.